Novolog (Pharm-Up 1966) Past Earnings Performance
Past criteria checks 0/6
Novolog (Pharm-Up 1966)'s earnings have been declining at an average annual rate of -24.6%, while the Healthcare industry saw earnings growing at 11.4% annually. Revenues have been growing at an average rate of 12% per year.
Key information
-24.6%
Earnings growth rate
-26.6%
EPS growth rate
Healthcare Industry Growth | 14.9% |
Revenue growth rate | 12.0% |
Return on equity | -1.2% |
Net Margin | -0.4% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)
Nov 05Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital
Jul 25I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease
May 07Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend
Apr 14Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality
Mar 24Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 09How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?
Feb 15Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years
Jan 25How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?
Dec 29With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting
Dec 08Revenue & Expenses Breakdown
How Novolog (Pharm-Up 1966) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,728 | -6 | 117 | 0 |
30 Jun 24 | 1,683 | -18 | 122 | 0 |
31 Mar 24 | 1,668 | -20 | 124 | 0 |
31 Dec 23 | 1,643 | -42 | 123 | 0 |
30 Sep 23 | 1,630 | 15 | 117 | 0 |
30 Jun 23 | 1,597 | 24 | 110 | 0 |
31 Mar 23 | 1,546 | 25 | 105 | 0 |
31 Dec 22 | 1,508 | 48 | 102 | 0 |
30 Sep 22 | 1,424 | 43 | 86 | 0 |
30 Jun 22 | 1,366 | 43 | 80 | 0 |
31 Mar 22 | 1,315 | 41 | 76 | 0 |
31 Dec 21 | 1,255 | 42 | 84 | 0 |
30 Sep 21 | 1,229 | 41 | 82 | 0 |
30 Jun 21 | 1,190 | 40 | 81 | 0 |
31 Mar 21 | 1,148 | 40 | 79 | 0 |
31 Dec 20 | 1,134 | 40 | 64 | 0 |
30 Sep 20 | 1,085 | 38 | 62 | 0 |
30 Jun 20 | 1,061 | 24 | 59 | 0 |
31 Mar 20 | 1,042 | 18 | 57 | 0 |
31 Dec 19 | 1,004 | 10 | 64 | 0 |
30 Sep 19 | 1,000 | 9 | 61 | 0 |
30 Jun 19 | 963 | 18 | 59 | 0 |
31 Mar 19 | 943 | 22 | 56 | 0 |
31 Dec 18 | 910 | 23 | 49 | 0 |
30 Sep 18 | 912 | 22 | 49 | 0 |
30 Jun 18 | 891 | 23 | 46 | 0 |
31 Mar 18 | 862 | 22 | 43 | 0 |
31 Dec 17 | 839 | 23 | 44 | 0 |
30 Sep 17 | 797 | 23 | 37 | 0 |
30 Jun 17 | 780 | 24 | 35 | 0 |
31 Mar 17 | 770 | 27 | 34 | 0 |
31 Dec 16 | 739 | 29 | 32 | 0 |
30 Sep 16 | 730 | 28 | 32 | 0 |
31 Dec 15 | 683 | 25 | 30 | 0 |
31 Dec 14 | 629 | 24 | 29 | 0 |
31 Dec 13 | 543 | 15 | 27 | 0 |
Quality Earnings: NVLG is currently unprofitable.
Growing Profit Margin: NVLG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NVLG is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.
Accelerating Growth: Unable to compare NVLG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVLG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.6%).
Return on Equity
High ROE: NVLG has a negative Return on Equity (-1.15%), as it is currently unprofitable.